Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Afatinib Dimaleate

FDA-approved product (tablet, oral), marketed as Afatinib Dimaleate, Gilotrif.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Afatinib Dimaleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Non-small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Afatinib Dimaleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.9 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Afatinib Dimaleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

    NCT02044380 · start 2014-03

    Registered record
    Registry ID
    NCT02044380
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03
    Completion
    2016-02
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAfatinib
    PhasePhase 3
    Registry statusCompleted

  • Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation

    NCT01836341 · start 2013-04

    Registered record
    Registry ID
    NCT01836341
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    Afatinib; Cisplatin; Carboplatin; Pemetrexed; Radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2013-04
    Completion
    2015-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionAfatinib; Cisplatin; Carboplatin; Pemetrexed +1 more
    PhasePhase 1
    Registry statusWithdrawn

  • Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients

    NCT01415011 · start 2012-12

    Registered record
    Registry ID
    NCT01415011
    Conditions
    Carcinoma, Non-Small-Cell Lung
    Interventions
    Afatinib (BIBW 2992)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-12
    Completion
    2018-11-30
    Enrolment
    39

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-Small-Cell Lung
    InterventionAfatinib (BIBW 2992)
    PhasePhase 2
    Registry statusCompleted

  • A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.

    NCT01732640 · start 2012-12

    Registered record
    Registry ID
    NCT01732640
    Conditions
    Squamous Cell Carcinoma of the Head and Neck
    Interventions
    Afatinib; Paclitaxel; Carboplatin; Cisplatin; Intensity Modulated Radiation Therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Terminated
    Start
    2012-12
    Completion
    2017-01
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSquamous Cell Carcinoma of the Head and Neck
    InterventionAfatinib; Paclitaxel; Carboplatin; Cisplatin +1 more
    PhasePhase 1 / Phase 2
    Registry statusTerminated

  • Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

    NCT01649271 · start 2012-07-23

    Registered record
    Registry ID
    NCT01649271
    Conditions
    Breast Neoplasms; Stomach Neoplasms
    Interventions
    Herceptin; afatinib; trastuzumab; Herceptin; afatinib; afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-07-23
    Completion
    2016-06-23
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Neoplasms; Stomach Neoplasms
    InterventionHerceptin; afatinib; trastuzumab; Herceptin +2 more
    PhasePhase 1
    Registry statusCompleted

  • Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck

    NCT01538381 · start 2012-07

    Registered record
    Registry ID
    NCT01538381
    Conditions
    Carcinoma, Squamous Cell of Head and Neck
    Interventions
    Afatinib; Observation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07
    Completion
    2015-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Squamous Cell of Head and Neck
    InterventionAfatinib; Observation
    PhasePhase 2
    Registry statusCompleted

  • Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis

    NCT01776684 · start 2012-06

    Registered record
    Registry ID
    NCT01776684
    Conditions
    EGFR Mutation Positive Non-small Cell Lung Cancer
    Interventions
    EGFR TKIs (gefitinib, erlotinib, afatinib, et al)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2012-06
    Completion
    2015-05
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEGFR Mutation Positive Non-small Cell Lung Cancer
    InterventionEGFR TKIs (gefitinib, erlotinib, afatinib, et al)
    PhaseNot applicable
    Registry statusUnknown

  • Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

    NCT01522768 · start 2012-03

    Registered record
    Registry ID
    NCT01522768
    Conditions
    Esophageal Cancer; Gastric Cancer
    Interventions
    Afatinib and Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-03
    Completion
    2023-02-20
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEsophageal Cancer; Gastric Cancer
    InterventionAfatinib and Paclitaxel
    PhasePhase 2
    Registry statusCompleted

  • A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

    NCT01480141 · start 2012-01

    Registered record
    Registry ID
    NCT01480141
    Conditions
    Lung Cancer
    Interventions
    BIBW 2992 (Afatinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2012-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionBIBW 2992 (Afatinib)
    PhasePhase 2
    Registry statusWithdrawn

  • BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

    NCT01320280 · start 2011-05

    Registered record
    Registry ID
    NCT01320280
    Conditions
    Refractory Cancer
    Interventions
    BIBW 2992 (Afatinib)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2011-05
    Completion
    2012-11
    Enrolment
    29

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Cancer
    InterventionBIBW 2992 (Afatinib)
    PhasePhase 2
    Registry statusTerminated

  • A Study of DS-2248 in Participants With Advanced Solid Tumors

    NCT01288430 · start 2011-03-29

    Registered record
    Registry ID
    NCT01288430
    Conditions
    Solid Tumors; Non-small Cell Lung Carcinoma
    Interventions
    DS-2248
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2011-03-29
    Completion
    2014-02-13
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSolid Tumors; Non-small Cell Lung Carcinoma
    InterventionDS-2248
    PhasePhase 1
    Registry statusTerminated

  • Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib

    NCT01298063 · start 2011-02

    Registered record
    Registry ID
    NCT01298063
    Conditions
    Liver Diseases; Healthy
    Interventions
    Afatinib; Afatinib; Afatinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-02
    Completion
    Not recorded
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Diseases; Healthy
    InterventionAfatinib; Afatinib; Afatinib
    PhasePhase 1
    Registry statusCompleted

  • An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours

    NCT01206816 · start 2010-10-04

    Registered record
    Registry ID
    NCT01206816
    Conditions
    Neoplasms
    Interventions
    BI 6727 + BIBW 2992
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10-04
    Completion
    2012-11-15
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionBI 6727 + BIBW 2992
    PhasePhase 1
    Registry statusCompleted

  • BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

    NCT01214616 · start 2010-10-01

    Registered record
    Registry ID
    NCT01214616
    Conditions
    Neoplasms
    Interventions
    afatinib 20mg; afatinib 40mg; vinorelbine IV 25 or 20mg/m2
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-10-01
    Completion
    2013-05-01
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    Interventionafatinib 20mg; afatinib 40mg; vinorelbine IV 25 or 20mg/m2
    PhasePhase 1
    Registry statusCompleted

  • BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC

    NCT01156545 · start 2010-10

    Registered record
    Registry ID
    NCT01156545
    Conditions
    Non-small Cell Lung Cancer
    Interventions
    BIBW 2992; simvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-10
    Completion
    2021-06-09
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer
    InterventionBIBW 2992; simvastatin
    PhasePhase 2
    Registry statusCompleted